F. Stephen Hodi
0000-0001-6825-091X
Publication & Citation Trends
Publications
0 total
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) OA
Cited by 40
Semantic Scholar
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) OA
Cited by 14
Semantic Scholar
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. OA
Cited by 673
Semantic Scholar
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain OA
Cited by 1,085
Semantic Scholar
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma OA
Cited by 3,326
Semantic Scholar
Melanoma and immunotherapy bridge 2015 OA
Cited by 22
Semantic Scholar
Ludwig Presence at 2015 ASCO Annual Meeting
Cited by 0
Semantic Scholar
Combination boosts survival for metastatic melanoma
Cited by 0
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(839)
CAR-T cell therapy research
(426)
Immunotherapy and Immune Responses
(366)
Melanoma and MAPK Pathways
(265)
Cutaneous Melanoma Detection and Management
(109)
Affiliations
Université Paris-Sud
The Wistar Institute
Broad Institute
Boston University
New England Biolabs (United States)